Intelligent Clinical Systems

Voice Activated Supply Retrieval For Clinical Environments

Countdown clock
Exclusive
Friends Invest First
Soft Launch Until Jul 15 @ 12:00 PM ET
--
day
--
hour
--
min
--
sec
INVESTMENT TERMS
Future Equity
 $20M  $17M valuation cap
Early Bird Bonus: The first $250K of investments will be in a SAFE with a $17M valuation cap

Highlights

1
National Science Foundation - Phase I Invitation
2
Main Stage Winner / Catalyst Award - Idea Funding Tucson
3
TechConnect World 2026 Critical Technology Spotlight and Oral Presenter
4
Venture Madness 2026 - Selected Presenter

Team


Pitch Deck

1 /

Welcome to the Era of Ambient Intelligence

The Problem

Supply locations are memory dependent. New, float, and agency staff are at risk the moment they walk into a room they’ve never worked in, and even veterans lose time in the supply room daily. Memory degrades under stress, and the high-stress moments of acute care are exactly when clinical recall fails hardest. Billions have gone into electronic health records; the supply room is still analog.

A Note From Our Founder

Meet Ambi

So we built one. Ambi is a voice-activated, LED-guided supply retrieval system that lives directly on the supply rack. A clinician walks up, speaks the item they need, and Ambi illuminates the exact slot in seconds. No screens. No apps. No cloud. No PHI. Just the rack, the voice, and the light.

Under the hood, Ambi’s on-device speech recognition classifies the request, fuses it with long-term usage priors and short-term recency signals, and lights the correct slot in under a second. If the network goes down or the hospital loses power to the server room, Ambi keeps working.

Why it’s Different: A Deterministic Embedded System

Ambi runs on DECA, our Deterministic Edge Control Architecture closer in lineage to aerospace and medical-device systems than to cloud AI. It’s built for environments where “mostly works” isn’t an option.

It installs on any existing rack in about 30 minutes, no construction, no IT integration, no capital-committee approval.

Why Now

Four forces converge at this exact moment: edge AI is finally practical on ultra-low-power microcontrollers; hospital operational strain has made nurse retention a board-level crisis; on-device compute has become a security requirement, not a preference; and hospitals want retrofit solutions they can deploy without construction or procurement cycles.

Validation & Traction

ICS is pre-revenue with a validated prototype. The recognition below cleared bars most early companies never reach, and we’re honest that paying pilots are still ahead of us, not behind. Securing the first written pilot commitment is the next milestone.

Market Opportunity

We start where the stakes are highest and the pain is most documented, the hospital. But DECA doesn’t change between verticals; the vocabulary changes, the buyer changes, the architecture does not. The same system that guides a nurse to an 18-gauge IV can guide a soldier to a field kit or a technician to the right component.

Business Model & Unit Economics

Hardware up front plus recurring per-rack SaaS. A 250-rack hospital is roughly $1M in hardware and $120K in ARR, with customer ROI in under six months on recovered nurse time. Low capex means department-level approval, not the capital committee.

Competition

ERP systems, RFID/RTLS, smart cabinets, and pick-to-light all answer “what’s in stock?” Ambi answers the question a nurse actually has mid-shift: “where is it, right now?” They track inventory. We drive execution.

Roadmap

The campaign launches after the non-provisional patent filing. The milestones ahead:

Reasons to Invest

As with any early-stage hardware + healthcare company, this opportunity is subject to scientific, execution, regulatory, and commercialization risks.

The Ask & Use of Funds

ICS is raising on a SAFE through Regulation CF on Wefunder, launching after the non-provisional patent filing. Proceeds fund pilot deployments, the engineering team, DECA development, the patent filing, clinical benchmarking, and the data that unlocks NSF Phase I, getting Ambi into the hands of nurses providing care in hospitals in your community. Planned allocation: engineering 40% · sales & pilots 25% · operations 15% · G&A 10% · reserve 10%.

Risks

As with any early-stage company, this opportunity carries significant risk. ICS is pre-revenue; the product is in development and its performance figures are current design targets subject to clinical validation. The business depends on converting pilots to paying contracts, on the timing of the patent filing, and on manufacturing and regulatory execution. Results may differ from current expectations. Full risk factors will be disclosed in the Form C.

FAQ

Overview